A Point System Table to Estimate the Risk of Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy: The LIFE Study
暂无分享,去创建一个
P. Okin | R. Devereux | S. Kjeldsen | S. Julius | K. Wachtell | D. Hille
[1] C. Choi,et al. Estimating the probability of stroke in Korean hypertensive patients visiting tertiary hospitals using a risk profile from the framingham study , 2009, BMC neurology.
[2] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[3] J. Hippisley-Cox,et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study , 2007, BMJ : British Medical Journal.
[4] M. Weir. Microalbuminuria and cardiovascular disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[5] N. Cook,et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.
[6] Ying Zhang,et al. Prediction of Coronary Heart Disease in a Population With High Prevalence of Diabetes and Albuminuria: The Strong Heart Study , 2006, Circulation.
[7] M. Woodward,et al. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) , 2005, Heart.
[8] Ralph B D'Agostino,et al. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. , 2005, Statistics in medicine.
[9] J. Edelman,et al. Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study , 2004, Journal of Human Hypertension.
[10] M. Nieminen,et al. Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.
[11] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[12] M. Nieminen,et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.
[13] Steven Snapinn,et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.
[14] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[15] François Gueyffier,et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials , 2001, BMJ : British Medical Journal.
[16] S. Pocock,et al. Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. , 1999, Circulation.
[17] M. Nieminen,et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. , 1998, Hypertension.
[18] M. Nieminen,et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. , 1997, American journal of hypertension.
[19] Daniel L. McGee,et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. , 1995, JAMA.
[20] B. Dahlöf,et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.
[21] J. Laragh,et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.
[22] R B D'Agostino,et al. Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.
[23] M. Bayes,et al. The Probability of , 2001 .
[24] S. Kjeldsen,et al. Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment. , 1996, Blood pressure.
[25] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[26] D E Manyari,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.